Latest News
We are lookin for mid-cap U.S. companies that show low valuation
Insmed, Agios rise; DraftKings, Atlantica fall, Tuesday, 5/28/2024
Stocks that traded heavily or had substantial price changes on Tuesday: Insmed, Agios rise; DraftKings, Atlantica fall
Corcept Therapeutics, PNM Resources fall; Johnson & Johnson rise, Tuesday, 1/2/2024
Stocks that traded heavily or had substantial price changes on Tuesday: Corcept Therapeutics, PNM Resources fall; Johnson & Johnson rise
BridgeBio, Corcept rise; Aclaris Therapeutics, IAA fall
Stocks that traded heavily or had substantial price changes Monday: BridgeBio, Corcept rise; Aclaris Therapeutics, IAA fall
NATIONALLY RANKED ROSEN LAW FIRM Encourages Corcept Therapeutics Incorporated Investors to Inquire About Class Action Investigation - CORT
/PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of...
EQUITY ALERT: Rosen Law Firm Encourages Corcept Therapeutics Incorporated Investors to Inquire About Class Action Investigation – CORT
WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Corcept Therapeutics Incorporated (NASDAQ: CORT).
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Corcept Therapeutics Incorporated and Encourages Investors with Losses to Contact the Firm
The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Corcept Therapeutics Incorporated (“Corcept” or “the Company”) (NASDAQ: CORT ) for violations of the...
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Corcept Therapeutics Incorporated and Encourages Investors with Losses to Contact the Firm
The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Corcept Therapeutics Incorporated (“Corcept” or “the Company”) (NASDAQ: CORT ) for violations of the...
These 3 Stocks Are Winning the Bear Market -- Here's How
Picking the right markets to compete in makes surviving bear markets much more manageable for these companies.
Corcept Therapeutics (CORT) Q2 2022 Earnings Call Transcript
CORT earnings call for the period ending June 30, 2022.
Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update
MENLO PARK, Calif., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the...
Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call
MENLO PARK, Calif., July 27, 2022 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report second quarter...
Corcept Therapeutics Initiates Rosella – A Pivotal Phase 3 Trial in Recurrent, Platinum-Resistant Ovarian Cancer
Phase 2 trial showed that relacorilant plus nab-paclitaxel improved progression-free survival, duration of response and overall survival without an...
Corcept Therapeutics to Start Phase 3 Trial of Relacorilant Plus Nab-Paclitaxel in Patients With Platinum-Resistant Ovarian Cancer
Positive results of preceding Phase 2 trial to be featured in oral presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting ...
Corcept Therapeutics (CORT) Q1 2022 Earnings Call Transcript
CORT earnings call for the period ending March 31, 2022.
Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call
MENLO PARK, Calif., April 28, 2022 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report first quarter...
3 Small-Cap Medical Stocks With Big Momentum
Now is a good time to take a closer look at these stocks.
Corcept Therapeutics Announces Appointment of Three Senior Leaders
Key Hires Bring Diverse Expertise to Commercial and Development Initiatives...
Corcept Therapeutics Completes Enrollment in Phase 2 GRATITUDE Study of Miricorilant in Patients with Antipsychotic-Induced Weight Gain
Data to be Available in Fourth Quarter 2022...
Relacorilant Plus Nab-Paclitaxel Extends Survival in Women with Recurrent, Platinum-resistant Ovarian Cancer
Addition of relacorilant to nab-paclitaxel reduces risk of death by 33 percent compared to treatment with nab-paclitaxel alone (p-value: 0.066), without...
3 Reasons Why Corcept Therapeutics Is a Better Buy Than Shiba Inu Coin
Making medicines is a more reliable path to share price appreciation than memes.
Corcept Therapeutics (CORT) Q4 2021 Earnings Call Transcript
CORT earnings call for the period ending December 31, 2021.
Corcept Therapeutics Announces Fourth Quarter and Full-Year 2021 Audited Financial Results and Provides Corporate Update
MENLO PARK, Calif., Feb. 15, 2022 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial stage company engaged in the...
Corcept Therapeutics to Announce Fourth Quarter and Full-year 2021 Financial Results, Provide Corporate Update and Host Conference Call
MENLO PARK, Calif., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report fourth quarter and...
Shareholder Alert: Robbins LLP Is Investigating the Officers and Directors of Corcept Therapeutics Incorporated (CORT)
Shareholder rights law firm Robbins LLP is investigating the officers and directors of Corcept Therapeutics Incorporated (NASDAQ: CORT) for breaches of fiduciary duty, mismanagement, corporate waste, and violations of the securities laws....